ID

45874

Description

Principal Investigator: Gail Jarvik, MD, PhD, University of Washington, Seattle, WA, USA MeSH: Colorectal Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000999 The Clinical Sequencing Exploratory Research (CSER) program supports multi-disciplinary projects that bring together clinicians, bioinformaticians, and ethicists to research the challenges of utilizing genomic sequence data in the clinic in the routine practice of medicine. The challenges are many and not disease-specific. Important aims of the research include: development of technical specifications and standards for sequencing in a clinical setting, investigation of methods to transmit genome-scale data to physicians in a fashion and timescale that fits the normal clinical workflow, exploration of regulatory requirements for applying genomic sequence data to patient care, study of physician and patient preferences regarding presentation of genomic information, and study of the ethical implications of returning unanticipated findings. More information about CSER and the investigators and institutions who comprise the CSER consortium can be found at http://www.genome.gov/27546194. The NEXT (New Exome Technology) Medicine Study utilizes a randomized controlled trial (RCT) structure to compare usual care (UC) practice in Medical Genetics Clinics with the introduction of a powerful research tool of whole exome sequencing plus UC practices for Colorectal Cancer and Polyposis (CRCP) in adults. In doing so, the study aims to explore the practical, economic, and ethical implications of identifying and returning incidental findings ("extra" whole exome genetic risk results not associated with CRCP that includes pharmacogenetic variants) to patients. The study will also attempt to identify novel causal genes for CRCP by studying relatives of selected research subjects.

Link

dbGaP study = phs000999

Keywords

Versions (1)
  1. 10/27/23 10/27/23 - Simon Heim
Copyright Holder

Gail Jarvik, MD, PhD, University of Washington, Seattle, WA, USA

Uploaded on

October 27, 2023

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

dbGaP phs000999 CSER: Clinical Sequencing in Cancer: Clinical, Ethical, and Technological Studies

English

Eligibility Criteria

5 forms  
Inclusion and exclusion criteria
Description

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
Subjects originate as patients that have come for a first time visit a Medical Genetics clinic to investigate their apparent inherited CRCP risk. After patients have completed their first clinical visit, they are approached for possible study participation. Subjects are randomized to either arm and later told of the determination after they complete their scheduled clinical results visit (RRV1-Return of CRCP results from UC or UC + WXS). Approximately one month later, all subjects return to the clinic for the research visit RRV2 where WXS subjects receive incidental findings results from exome sequencing and UC subjects have an extended CRCP risk discussion. During this time period and for approximately 1 year more, subjects complete surveys and questionnaires that address the psychosocial/economic aspects of participation in this study. Some subjects are also asked to participate in "Focus Groups" or "Patient Interviews" that comprises a separate minimal risk IRB review.
Description

Subjects originate as patients that have come for a first time visit a Medical Genetics clinic to investigate their apparent inherited CRCP risk. After patients have completed their first clinical visit, they are approached for possible study participation. Subjects are randomized to either arm and later told of the determination after they complete their scheduled clinical results visit (RRV1-Return of CRCP results from UC or UC + WXS). Approximately one month later, all subjects return to the clinic for the research visit RRV2 where WXS subjects receive incidental findings results from exome sequencing and UC subjects have an extended CRCP risk discussion. During this time period and for approximately 1 year more, subjects complete surveys and questionnaires that address the psychosocial/economic aspects of participation in this study. Some subjects are also asked to participate in "Focus Groups" or "Patient Interviews" that comprises a separate minimal risk IRB review.

Data type

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0030705
UMLS CUI [1,3]
C5204638
UMLS CUI [1,4]
C1552784
UMLS CUI [1,5]
C1173690
UMLS CUI [2,1]
C4287881
UMLS CUI [2,2]
C5418626
UMLS CUI [2,3]
C0681850
UMLS CUI [2,4]
C0034656
UMLS CUI [2,5]
C5400986
UMLS CUI [2,6]
C0008952
UMLS CUI [2,7]
C1446911
UMLS CUI [2,8]
C1173690
UMLS CUI [3,1]
C1442880
UMLS CUI [3,2]
C0035168
UMLS CUI [3,3]
C0545082
UMLS CUI [3,4]
C0743997
UMLS CUI [3,5]
C5575842
UMLS CUI [3,6]
C1853667
UMLS CUI [4,1]
C1948053
UMLS CUI [4,2]
C0681850
UMLS CUI [4,3]
C0034394
UMLS CUI [4,4]
C0243156
UMLS CUI [4,5]
C0013556
UMLS CUI [4,6]
C5418626
UMLS CUI [4,7]
C0016400
UMLS CUI [4,8]
C0683518
UMLS CUI [4,9]
C5669842
Back to the top of the page

Similar models

Eligibility Criteria

5 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Subjects originate as patients that have come for a first time visit a Medical Genetics clinic to investigate their apparent inherited CRCP risk. After patients have completed their first clinical visit, they are approached for possible study participation. Subjects are randomized to either arm and later told of the determination after they complete their scheduled clinical results visit (RRV1-Return of CRCP results from UC or UC + WXS). Approximately one month later, all subjects return to the clinic for the research visit RRV2 where WXS subjects receive incidental findings results from exome sequencing and UC subjects have an extended CRCP risk discussion. During this time period and for approximately 1 year more, subjects complete surveys and questionnaires that address the psychosocial/economic aspects of participation in this study. Some subjects are also asked to participate in "Focus Groups" or "Patient Interviews" that comprises a separate minimal risk IRB review.
Item
Subjects originate as patients that have come for a first time visit a Medical Genetics clinic to investigate their apparent inherited CRCP risk. After patients have completed their first clinical visit, they are approached for possible study participation. Subjects are randomized to either arm and later told of the determination after they complete their scheduled clinical results visit (RRV1-Return of CRCP results from UC or UC + WXS). Approximately one month later, all subjects return to the clinic for the research visit RRV2 where WXS subjects receive incidental findings results from exome sequencing and UC subjects have an extended CRCP risk discussion. During this time period and for approximately 1 year more, subjects complete surveys and questionnaires that address the psychosocial/economic aspects of participation in this study. Some subjects are also asked to participate in "Focus Groups" or "Patient Interviews" that comprises a separate minimal risk IRB review.
boolean
C0681850 (UMLS CUI [1,1])
C0030705 (UMLS CUI [1,2])
C5204638 (UMLS CUI [1,3])
C1552784 (UMLS CUI [1,4])
C1173690 (UMLS CUI [1,5])
C4287881 (UMLS CUI [2,1])
C5418626 (UMLS CUI [2,2])
C0681850 (UMLS CUI [2,3])
C0034656 (UMLS CUI [2,4])
C5400986 (UMLS CUI [2,5])
C0008952 (UMLS CUI [2,6])
C1446911 (UMLS CUI [2,7])
C1173690 (UMLS CUI [2,8])
C1442880 (UMLS CUI [3,1])
C0035168 (UMLS CUI [3,2])
C0545082 (UMLS CUI [3,3])
C0743997 (UMLS CUI [3,4])
C5575842 (UMLS CUI [3,5])
C1853667 (UMLS CUI [3,6])
C1948053 (UMLS CUI [4,1])
C0681850 (UMLS CUI [4,2])
C0034394 (UMLS CUI [4,3])
C0243156 (UMLS CUI [4,4])
C0013556 (UMLS CUI [4,5])
C5418626 (UMLS CUI [4,6])
C0016400 (UMLS CUI [4,7])
C0683518 (UMLS CUI [4,8])
C5669842 (UMLS CUI [4,9])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial